Actively Recruiting
Phase 2 Study of Acoustic Cluster Therapy with Modified FOLFIRINOX Chemotherapy for Locally Advanced Pancreatic Cancer
Led by EXACT Therapeutics AS · Updated on 2026-04-03
25
Participants Needed
10
Research Sites
30 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the safety and effectiveness of Acoustic Cluster Therapy ACT combined with chemotherapy in treating patients with Locally Advanced Pancreatic Cancer LAPC who have not received prior treatment for their pancreatic cancer. This Phase 2 study aims to assess how well ACT, given alongside modified FOLFIRINOX chemotherapy, works for this condition. Participants receive ACT treatment, which includes the drug PS101 combined with ultrasound applied directly to the tumor, on the first day of each chemotherapy cycle. Chemotherapy with modified FOLFIRINOX is given in up to eight 2-week cycles. Patients are monitored throughout treatment for side effects and overall health. During the study, participants will have CT scans every 8 weeks to evaluate tumor response. Researchers will measure the overall response rate, tumor size changes, treatment side effects, survival rates, and potential eligibility for surgery. The trial lasts up to 24 weeks, during which safety and treatment effects are closely tracked.
CONDITIONS
Brief Title
Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
